Drug intelligence / Profile preview

PTI-901

Development stage: Discontinued
Lead developer: Cassava Sciences
Modality: Small Molecules
Administration: Oral

Overview

PTI-901 is a low-dose formulation of naltrexone hydrochloride, a small molecule opioid antagonist, developed by Pain Therapeutics for the treatment of irritable bowel syndrome (IBS). The drug's mechanism of action involves the selective blockade of excitatory opioid receptors at very low doses, which is intended to alleviate pain and improve overall bowel function without triggering the inhibitory effects typically associated with higher doses of opioid antagonists. Despite showing efficacy in a pilot study, PTI-901 failed to achieve its primary endpoint in a Phase III clinical trial, leading Pain Therapeutics to discontinue its development in December 2005.

Other names: low-dose naltrexone hydrochloride

Targets

DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on PTI-901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTI-901.

Explore the full profile